Chiome Bioscience

Chiome Bioscience Debt

The Debt of Chiome Bioscience (4583.T) as of Oct 16, 2026 is 261.70 M JPY. In the previous year, Debt was 281.50 M JPY — a change of -7.03% (lower).

Debt

261.70 MJPY

YoY

-7.03%

Last updated:

In 2025, Chiome Bioscience's total debt was 261.70 M JPY, a -7.03% change from the 281.50 M JPY total debt recorded in the previous year.

The Chiome Bioscience Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 JPY
Jan 1, 2019
-554,000.00 JPY
Jan 1, 2020
180.00 M JPY
Jan 1, 2021
183.00 M JPY
Jan 1, 2022
184.00 M JPY
Jan 1, 2023
291.00 M JPY
Jan 1, 2024
281.50 M JPY
Jan 1, 2025
261.70 M JPY
The Chiome Bioscience Debt history
YEARDebtYoY
261.70 MJPY-7.03%
281.50 MJPY-3.26%
291.00 MJPY+58.15%
184.00 MJPY+0.55%
183.00 MJPY+1.67%
180.00 MJPY-32,590.97%
-554,000.00JPY—
0.00JPY-100.00%
4.16 MJPY-92.32%
54.16 MJPY-45.84%
100.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Chiome Bioscience Stock analysis

What does Chiome Bioscience do? Chiome Bioscience Inc is a Health Care company based in Shibuya-Ku, Japan. The company has 49 employees and went public on December 20, 2011. It operates in the Life Sciences Tools & Services industry. Chiome Bioscience develops and sells antibody drugs using the Autonomous Diversifying Library (ADLib) system. Its business segments include Drug Discovery, focusing on R&D of specific antibodies for pharmaceutical companies, and Drug Discovery Support, which develops lead antibodies for therapeutic drugs through collaborations with pharmaceutical firms in Japan and overseas. Chiome Bioscience is one of the most popular companies on Eulerpool.

Debt Details

Understanding Chiome Bioscience's Debt Structure

Chiome Bioscience's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Chiome Bioscience's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Chiome Bioscience’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Chiome Bioscience’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Chiome Bioscience stock

Debt of Chiome Bioscience is 261.70 M JPY in 2025.

Debt of Chiome Bioscience changed from 281.50 M JPY to 261.70 M JPY, representing a -7.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Chiome Bioscience since 2006 – with annual values, charts, and detailed analysis.

Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Chiome Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Chiome Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Chiome Bioscience